Biomed mainz
WebMar 21, 2024 · BERKELEY, Calif. and MAINZ, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company’s CFO, will present and host one-on-one … WebAug 16, 2024 · About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non ...
Biomed mainz
Did you know?
WebMar 15, 2024 · About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex ... WebMar 8, 2024 · Mainz Biomed is supporting this year’s Gastro Update, a series of two 2-day practical training events for healthcare professionals, led by renowned German …
WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. MYNZ (“Mainz … WebSep 7, 2024 · Mainz Biomed N.V. Condensed Consolidated Statements of Financial Position June 30, 2024 and December 31, 2024 (unaudited) June 30,
WebFeb 21, 2024 · BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to … WebOct 28, 2024 · About. Mainz Biomed B.V. ( NASDAQ: MYNZ) is a molecular genetics cancer diagnostic company incorporated in 2024. Mainz Biomed was formed to acquire …
WebFeb 21, 2024 · Anne Hennecke/Caroline Bergmann. +49 211 529252 20. [email protected]. In the US: Spectrum Science. Melissa Laverty/Valerie Enes. +1 540 272 6465. [email protected]. For investor ...
WebApr 10, 2024 · Mainz Biomed B.V. press release ( NASDAQ: MYNZ ): FY GAAP EPS of -$1.86. Revenue of $0.53M (-8.6% Y/Y). Recommended For You Medical Properties … ctrl swing masterWebApr 10, 2024 · BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the … earth\u0027s wobble effect on climateWebMainz Biomed B.V. Ordinary Shares (MYNZ) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ctrl swap capsWebMar 15, 2024 · Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether … ctrl swim platformWeb21 hours ago · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mainz Biomed B.V. with a $18.00 average price target, which is a 208.85% upside from current levels. earth\u0027s wobble on its axisWebApr 4, 2024 · BERKELEY, Calif. and MAINZ, Germany, April 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert ®, the … ctrlsysWebMar 15, 2024 · Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future ... earth\u0027s zenith